FitzsimonsRedevelopmentAuthorityRollsOutFirstPhaseofStrategicRefocusWithAppointmentof FourKeyLeadersintheBioscienceIndustrytoItsBoardofDirectors TheFitzsimonsRedevelopmentAuthority(FRA)isaddingfourofthearea'smostwellknownandsuccessful leadersintheBioscienceIndustrytoitsBoardofDirectors.Changeinboardcompositionistheresultofa strategicrefocusfortheFRA,andthoserecentlyappointedtotheboardinclude:DonaldM.Elliman,Jr.; WilliamFreytag,PhD;JamesC.T.Linfield;andDavidPerez. Aurora,CO,November15,2011Inastrategicefforttorefocusandstrengthenitsorganization,the FitzsimonsRedevelopmentAuthority(FRA)hascompletedaregimenofplanningtomakeadjustmentsinthe direction,roles,responsibilitiesandallocationofresourcesgoingforward.Theannouncementismadeby DeniseBrown,FRAInterimExecutiveDirector,whosays,"Ourfirsttacticinrefocusinvolvesaugmentingour boardofdirectorswithfourofthearea'smostwellknownandsuccessfulleadersinthebioscienceindustryto helpbuildprogramsandservicestoattractbiosciencecompaniestorelocatetoColoradoandkeepgrowing Coloradobasedbiosciencecompanieshere,addingtoouremploymentbase.Theactiontomodifytheboard accordinglywasapprovedinarecentboardaction." JoiningtheFRABoardareDonaldM.Elliman,Jr.,ExecutiveDirectoroftheCharlesC.

GatesCenterfor RegenerativeMedicineandStemCellBiologyandcurrentDirectorandformerChairoftheChildren'sHospital ColoradoBoardofDirectors;WilliamFreytag,PhD,formerChairmanandCEOofMyogen,Inc.;JamesC.T. Linfield,PartnerinChargeoftheColoradoofficeofCooleyLLP;andDavidPerez,PresidentandChief ExecutiveOfficerofCaridianBCT,becomingTerumoBCT. Browncontinues,"We'reverypleasedtowelcomeournewboardmembers.Theseleadersareactively involvedthebiosciencecommunitylocally,nationallyandinternationallyandmaintainthosecritical relationshipswithentrepreneurs,companiesandresearchgroupsrequiredtoguidetheFRAthroughitsnext phaseofgrowth.ThisisthefirsttimetheFRAhashadbioscienceexecutivesonitsboard." Asbackground,in1996,theCityofAuroraandUniversityofColoradoworkedtogethertocreateaspecial purposegovernmentalentity,givingitasinglemission:toimagineandgoverntheevolutionofahistoricarmy medicalcenterintooneoftheworldsmostforwardlookingbiosciencedistricts.Inpartnershipwiththe UniversityofColoradoandtheCityofAurora,theFRAacquiredmuchoftheformerarmysiteandbeganto implementanambitiousredevelopmentplanthatnowcomprisesthegrowingandthrivingFitzsimonsLife ScienceDistrictthatincludestheColoradoScience+TechnologyParknowadjacenttotheAnschutzMedical CampusandthenewV.A.hospitalcampus. "AstheFitzsimonssitehasmatured,it'sbecomecleartotheFRAboardthatitneededtodomoretosupport thegrowthofearlystageColoradobiosciencecompanies,especiallythosedevelopingtechnologiesfrom Colorado'sresearchinstitutions,withanemphasisonthosetechnologiesdevelopedattheAnschutzMedical Campus.Hence,theFRAisnowaddressingthecriticalneedtobringbiosciencefocusedleadershiptothe boardprocessinbuildingnewcorporatepartnershipsandleveragingthestrengthoftheAnschutzMedical CampusandtheFRA'srealestatedevelopmentpartner,theForestCityScience+TechnologyGroup,"Brown explains. More

Page2 NewFRABoardMembersBioscienceIndustryLeadership DonaldM.Elliman,Jr.(representingChildrensHospitalColoradoontheFRABoard)InFebruaryof2011,Mr. EllimanwasnamedExecutiveDirectoroftheCharlesC.GatesCenterforRegenerativeMedicineandStemCell Biology.FromJuneof2009toJanuaryof2011,DonservedasChiefOperatingOfficerforColorado.Inthatposition heassistedtheGovernorinthemanagementofallStateagencies.HewasalsotheChairoftheColoradoRecovery AccountabilityBoard,withresponsibilitiesforoversightofspendinginColoradoundertheAmericanRecoveryand ReinvestmentAct.From2007to2009,hewasDirectoroftheColoradoOfficeofEconomicDevelopmentand InternationalTrade,andfrom2000to2004,heservedfirstasPresidentofAscentSportsandthenasPresidentof KroenkeSportsEnterprises.HeretiredfromKroenkeashebecameChairoftheChildrensHospitalBoardandco chairofthecampaigntoraisefundsforthenewHospital.PriortohistimeatKroenke,Mr.EllimanworkedatTime Warnerforthirtytwoyears,retiringasanExecutiveVicePresidentofTimeInc.HecurrentlyservesontheBoards ofChildrensHospitalColorado,MiddleburyCollege,ColoradoStateUniversityandTheGatesFamilyFoundation. WilliamFreytag,PhDDr.Freytagcurrentlyservesasamemberoftheboardofdirectorsforthreehealthcare companies:GlobeImmune,BaroFold,andBiOptixInc.Dr.FreytagwasChairmanandChiefExecutiveOfficerof AsprevaPharmaceuticalsfromJuly2007untilitsmergerwithGalenicaAGinJanuary2008.PriortoAspreva,Dr. FreytagwasPresident,ChiefExecutiveOfficerandChairmanoftheBoardofDirectorsofMyogen,Inc.,acompany thatstartedinthebioscienceincubatoratFitzsimons,fromJuly1998untilMyogenwasacquiredbyGileadSciences inNovember2006.FromOctober1994toMay1998,Dr.FreytagwasaSeniorVicePresidentatSomatogen,Inc. PriortoSomatogen,DrFreytagwasPresidentofResearchandDevelopmentatBoehringerMannheimCorporation, aninternationalhealthcarecompany.HereceivedaB.S.fromPurdueUniversityandaPh.D.inbiochemistryfrom theUniversityofKansasMedicalCenter. JamesC.T.LinfieldAsPartnerinChargeoftheColoradoofficeofCooleyLLP,Mr.Linfield'spracticefocuseson representationofpublicandprivatetechnologycompaniesandventurecapitalfunds,withanemphasison corporatefinance,mergersandacquisitionsandstrategicalliances.Hehasdeepexperienceadvisingstartups, venturebackedcompanies,publicentitiesandinvestorsacrossawidevarietyofindustries,including biotechnologyandmedicaldevices.PriortojoiningCooley,Mr.Linfieldworkedinthebiotechnologyindustryfor twoandahalfyearsasChiefFinancialOfficerandGeneralCounselofSomatogen,Inc.,wherehehelpedleadthe companytoasuccessfulinitialpublicoffering.HereceivedhisA.B.magnacumlaudefromHarvardCollegeandhis J.D.magnacumlaudefromHarvardLawSchool.HealsoservesasChairoftheGovernorsAdvisoryCommitteeon VentureCapitalInvestment,isamemberoftheExecutiveCommitteeoftheColoradoBioScienceAssociation,and isamemberoftheTechnologyTransferAdvisoryBoardfortheUniversityofColorado. DavidPerezAsPresidentandChiefExecutiveOfficerofthecombinedbusinessesofCaridianBCTandTerumo TransfusionsoontobeTerumoBCT,Mr.PerezalsoservesasChairmanofTerumoCorporationsBlood ManagementBusinessboard.Heisresponsibleforleadingthestrategicdirection,growthandexecutionofthis combinedglobalorganizationwithrevenuesinexcessof$830million.Underhisleadershipdirection,the companieswillintegrateandinnovate,together,toservecustomersandtheirpatients,whoaretheultimate beneficiariesofthelifesavinggiftofblood.Adedicatedandactiveindustryleaderwithnearly30yearsof experiencewithinthemedicaldeviceandhealthcareindustries,Mr.Perezalsolendshisexpertisetonumerous boardsandcouncils.HeservestheAdvancedMedicalTechnologyAssociation(AdvaMed)ontheboardofdirectors andontheExecutiveCommittee,chairingboththeTechnologyandRegulatoryAffairsCommitteeandtheBlood ProductsandTechnologySector. More

Page3
Mr.PerezisalsochairoftheboardoftrusteesfortheNationalBloodFoundation(NBF);amemberoftheNBF CouncilonResearchandDevelopment;andaboardmemberoftheFoundationforAmerica'sBloodCentersand theColoradoBioScienceAssociation.PriortojoiningCaridianBCTin1999,heheldleadershippositionsat UroTherapiesInc.,HaemoneticsCorp.,CaremarkLLC,CoramHealthcareCorp.andKendall.Mr.Perezearnedhis bachelor'sdegreeinpoliticalsciencefromTexasTechUniversity.

OtherFRABoardmembersinclude:BruceBenson,President,UniversityofColorado;BruceSchroffel, President,UniversityofColoradoHospital;JohnShaw,Principal,McWhinney;LillyMarks,VicePresidentfor HealthAffairsandExecutiveViceChancelloroftheAnschutzMedicalCampus;DwightRider,Principal,Freund Investments;andCouncilwomanMelissaMillerfromAurorawhowillbejoinedbytwootherelectedofficials tobenamedbytheAuroraCityCouncil. AboutFitzsimonsRedevelopmentAuthority TheFRAdirectsthecommercialdevelopmentsintheFitzsimonsLifeScienceDistrict,alongwithitspartner, ForestCityScience+TechnologyGroup.Inthisrole,theFRAisdedicatedtoprovidinglifesciencecompanies: anenvironmentwheretheycanthrive;successenhancingresourcesliketheDistrictsincubatorfacilities;and servicesthathelpformconnectionsbetweenprivateindustryandtheUniversityofColorado.Auroras FitzsimonsLifeScienceDistrictisbecomingwhatitsfoundersenvisioned:afunctioningcommunitythat directlysupportsthehealthandwellbeingoflifesciencecompanies.Formoreinformation,visit: http://www.fitzscience.com. ### Contacts: VickiJenings,CPM,DirectorofBusinessRelations,FitzsimonsRedevelopmentAuthority http://www.fitzscience.com7208594108vjenings@colobio.com MaggieChamberlinHolben,APR,PrincipalAbsolutelyPublicRelationshttp://www.absolutelypr.com 3039849801and3036693558(cell),maggie@absolutelypr.com